Squarepoint Ops LLC Has $136,000 Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Squarepoint Ops LLC lowered its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 16.0% in the second quarter, Holdings Channel.com reports. The institutional investor owned 41,255 shares of the company’s stock after selling 7,838 shares during the quarter. Squarepoint Ops LLC’s holdings in Eton Pharmaceuticals were worth $136,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Westside Investment Management Inc. lifted its holdings in Eton Pharmaceuticals by 1.9% in the 1st quarter. Westside Investment Management Inc. now owns 573,960 shares of the company’s stock worth $2,152,000 after purchasing an additional 10,850 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Eton Pharmaceuticals by 13.7% in the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after purchasing an additional 18,898 shares during the period. Renaissance Technologies LLC raised its position in shares of Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares during the period. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in shares of Eton Pharmaceuticals in the second quarter worth $420,000. Institutional investors own 27.86% of the company’s stock.

Wall Street Analysts Forecast Growth

ETON has been the topic of a number of research analyst reports. Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, October 4th. HC Wainwright lifted their price objective on Eton Pharmaceuticals from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, October 4th.

Insider Buying and Selling

In other news, major shareholder Opaleye Management Inc. acquired 11,248 shares of Eton Pharmaceuticals stock in a transaction on Monday, October 7th. The stock was bought at an average price of $7.22 per share, for a total transaction of $81,210.56. Following the transaction, the insider now owns 2,730,000 shares of the company’s stock, valued at $19,710,600. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought a total of 85,600 shares of company stock valued at $462,674 over the last three months. 14.89% of the stock is owned by corporate insiders.

Eton Pharmaceuticals Stock Up 2.2 %

Shares of ETON stock opened at $8.00 on Monday. Eton Pharmaceuticals, Inc. has a 12 month low of $3.03 and a 12 month high of $8.03. The firm has a market cap of $205.53 million, a PE ratio of 200.00 and a beta of 1.31. The stock has a 50 day moving average of $5.11 and a 200-day moving average of $4.06.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. The company had revenue of $9.07 million during the quarter, compared to the consensus estimate of $10.00 million. As a group, equities analysts predict that Eton Pharmaceuticals, Inc. will post -0.17 EPS for the current fiscal year.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.